RIOUX PATRICE sold $111 of MNPR

RIOUX PATRICE sold 1 shares of Monopar Therapeutics (MNPR) at $111.26 on 2026-08-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RIOUX PATRICE
Published Aug 27, 2026, 11:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 11:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MNPR
Neutral
high confidence
Mentioned
$MNPR
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MNPRNeutralLow
01

Why it matters

The disclosed sale is too small to affect market perception of Monopar Therapeutics.

02

Market read

Routine insider sale with negligible market impact.

03

What to watch

The 10b5-1 plan indicates pre‑arranged execution, reducing the likelihood of insider sentiment.

Relevance 2/10Novelty 4/10Timing: post‑market filing on Aug 27 2026

Background

Form 4 filings disclose insider transactions; they are primary sources for insider activity.

Company-level read

Ticker impact

$MNPRNeutralHigh confidence
Context

Insider Patrice Rioux sold 1 share at $111.26 via a 10b5-1 plan, reducing holdings to 5,065 shares.

Expected impact

No material price impact expected.

Evidence & confidence

The transaction size ($111) is trivial and disclosed via a Form 4, which is a routine insider sale.

Market effects

None; the biotech sector is unaffected by a micro‑sale.

None; the filing is U.S.‑focused and does not affect regional markets.

None

Counterpoint

If the insider were a key executive, even a tiny sale could signal concerns, but here the holder is a minor insider.

Key entities

  • Monopar Therapeutics

    Biotech firm listed on NASDAQ under ticker MNPR.

  • Patrice Rioux

    Reporter of the Form 4 transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MNPRMed

Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, November 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative t

$MNPRMedAI 8/10

Monopar presents Wilson disease trial data at liver conference

Monopar Therapeutics (MNPR) presented Phase 3 FoCus trial data for Wilson disease at a liver conference. Key findings include high rates of cirrhosis, neurologic, and psychiatric symptoms among patients. ALXN1840, its investigational therapy, showed positive long-term data. The trial is the largest randomized controlled study in Wilson disease.

$MNPRMedAI 8/10

Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026

Monopar Therapeutics (MNPR) presented data from its Phase 3 FoCus trial at AASLD 2026, showing significant disease burden in Wilson disease patients, including cirrhosis, neurologic, and psychiatric symptoms. ALXN1840, Monopar's investigational therapy, demonstrated long-term safety with neutral molybdenum balance and normal uric acid levels over six years.

$MNPRLow

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates Wilmette, IL, August 12, 2026 – Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical‐stage biopharmaceutical company developing innovative tr

$MNPRMedAI 8/10

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

Monopar Therapeutics presented Phase 2 ALXN1840 (tiomolibdate choline) data at EASL 2026 for treatment-experienced Wilson disease patients. In an open-label, multicenter 48-week trial (29 patients; 24 with paired biopsies), histology showed stabilization or improvement in multiple liver measures, with no statistically significant change in hepatic copper. The company also reported significant improvements in UWDRS Part III, CGI, and EQ-5D UK, with generally nonserious Grade 1–2 adverse events.